CORDLIFE on Thursday (Jul 25) said its Hong Kong and Malaysian subsidiaries received re-accreditations from the Association for the Advancement of Blood & Biotherapies.
The association sets standards for blood banking, transfusion medicine, blood management and cellular therapies. Cordlife Hong Kong obtained its seventh re-accreditation, while Malaysia-based StemLife received its fourth, said the group.
StemLife also underwent an assessment and recertification for ISO 9001:2015 – an international standard for quality management systems.
The move comes as StemLife expands its range of services beyond cord-blood banking. This includes a partnership with Loh Guan Lye Specialists Centre to offer peripheral blood stem cell banking services to patients with cancer or blood disorders.
It also tied up with Medixcell Laboratory to harvest and bank mesenchymal stem cells from a newborn’s umbilical cord.
Cordlife Philippines is also expanding its services to include diagnostics tests and routine prenatal screenings.
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
In June, Cordlife sank into the red for the first quarter with a net loss of S$11.6 million for the three months ended Mar 31, versus a net profit of S$1.2 million in the corresponding quarter the year before.
The beleaguered private cord-blood bank has been grappling with the financial impact of refunding customers whose cord-blood samples were compromised by irregular temperatures in its storage tanks.
The incident led to a six-month suspension notice from Singapore’s Ministry of Health in November 2023, which was later extended by another three months starting Jun 15, 2024.
Refunds and waivers of subsequent fees Cordlife offered on Apr 8 to active clients with stored cord-blood units led to a revenue reversal of about S$9.7 million in Q1. This included the recognition of about S$500,000 in contract liabilities related to future storage obligations for its affected clients.
Excluding the refund’s financial impact, the group’s revenue for Q1 2024 would have been about S$9.4 million, a 33 per cent decline from the year-ago figure.
Negative publicity from the saga also affected Cordlife’s operations in other markets. Compared with the year-ago period, the number of samples stored in Q1 2024 fell by about a third in Indonesia, India and Malaysia.
Cordlife’s shares last traded at S$0.155 on Jul 17.
